Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 34Squamous Cell Carcinoma of Head and Neck 22Uterine Cervical Neoplasms 19Lung Neoplasms 19Small Cell Lung Carcinoma 16Oropharyngeal Neoplasms 14Ovarian Neoplasms 12Carcinoma 10Urinary Bladder Neoplasms 9Stomach Neoplasms 9Mouth Neoplasms 9Laryngeal Neoplasms 9Fallopian Tube Neoplasms 9Hypopharyngeal Neoplasms 8Cholangiocarcinoma 8Pancreatic Neoplasms 7Mesothelioma, Malignant 7Medulloblastoma 7Breast Neoplasms 7Adenocarcinoma of Lung 7Neuroblastoma 6Nasopharyngeal Carcinoma 6Gallbladder Neoplasms 6Ganglioneuroblastoma 5Brain Neoplasms 5Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Lymphoid Interstitial Pneumonia 4Head and Neck Neoplasms 4Esophageal Neoplasms 4

Interventions

pembrolizumab 1fludarabine phosphate 1fludarabine 1berzosertib 1aldesleukin 1Platinum 1Immunoglobulin G 1Gemcitabine 1Cyclophosphamide 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Bladder Urothelial Carcinoma × Platinum × Clear all
NCT02567409 2025-03-03

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
87 enrolled 13 charts
Genitourinary

Metastatic Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡